Hualan Biological EngineeringInc (002007) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hualan Biological EngineeringInc (002007) has a cash flow conversion efficiency ratio of 0.024x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥319.46 Million ≈ $46.75 Million USD) by net assets (CN¥13.25 Billion ≈ $1.94 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Hualan Biological EngineeringInc fund operations to measure how many days the company can operate on defensive assets alone.
Hualan Biological EngineeringInc - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Hualan Biological EngineeringInc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hualan Biological EngineeringInc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hualan Biological EngineeringInc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hang Zhou Iron & Steel Co Ltd
SHG:600126
|
0.124x |
|
OCI Co Ltd
KO:010060
|
0.117x |
|
Zhende Medical Co Ltd
SHG:603301
|
0.017x |
|
G-bits Network Technology Xiamen Co Ltd
SHG:603444
|
0.134x |
|
National Health Investors Inc
NYSE:NHI
|
0.035x |
|
Viohalco S.A
BR:VIO
|
0.050x |
|
Dhc Software Co Ltd
SHE:002065
|
0.047x |
|
FangDa Carbon New Material Co Ltd
SHG:600516
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Hualan Biological EngineeringInc (2003–2024)
The table below shows the annual cash flow conversion efficiency of Hualan Biological EngineeringInc from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see 002007 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥13.85 Billion ≈ $2.03 Billion |
CN¥1.06 Billion ≈ $155.02 Million |
0.077x | -23.71% |
| 2023-12-31 | CN¥13.42 Billion ≈ $1.96 Billion |
CN¥1.35 Billion ≈ $196.94 Million |
0.100x | +27.90% |
| 2022-12-31 | CN¥12.21 Billion ≈ $1.79 Billion |
CN¥957.31 Million ≈ $140.08 Million |
0.078x | -50.39% |
| 2021-12-31 | CN¥9.06 Billion ≈ $1.33 Billion |
CN¥1.43 Billion ≈ $209.62 Million |
0.158x | -3.40% |
| 2020-12-31 | CN¥8.10 Billion ≈ $1.19 Billion |
CN¥1.33 Billion ≈ $193.93 Million |
0.164x | -17.35% |
| 2019-12-31 | CN¥6.88 Billion ≈ $1.01 Billion |
CN¥1.36 Billion ≈ $199.41 Million |
0.198x | -11.60% |
| 2018-12-31 | CN¥5.77 Billion ≈ $844.71 Million |
CN¥1.29 Billion ≈ $189.15 Million |
0.224x | +511.14% |
| 2017-12-31 | CN¥4.84 Billion ≈ $708.55 Million |
CN¥177.42 Million ≈ $25.96 Million |
0.037x | -50.74% |
| 2016-12-31 | CN¥4.44 Billion ≈ $649.04 Million |
CN¥329.94 Million ≈ $48.28 Million |
0.074x | -47.33% |
| 2015-12-31 | CN¥3.88 Billion ≈ $568.41 Million |
CN¥548.62 Million ≈ $80.28 Million |
0.141x | +3.30% |
| 2014-12-31 | CN¥3.64 Billion ≈ $532.05 Million |
CN¥497.15 Million ≈ $72.75 Million |
0.137x | -11.36% |
| 2013-12-31 | CN¥3.31 Billion ≈ $484.47 Million |
CN¥510.70 Million ≈ $74.73 Million |
0.154x | -11.73% |
| 2012-12-31 | CN¥2.83 Billion ≈ $414.24 Million |
CN¥494.69 Million ≈ $72.39 Million |
0.175x | +34.26% |
| 2011-12-31 | CN¥2.58 Billion ≈ $377.67 Million |
CN¥335.93 Million ≈ $49.16 Million |
0.130x | -48.63% |
| 2010-12-31 | CN¥2.41 Billion ≈ $352.04 Million |
CN¥609.53 Million ≈ $89.19 Million |
0.253x | -22.62% |
| 2009-12-31 | CN¥1.86 Billion ≈ $271.60 Million |
CN¥607.73 Million ≈ $88.93 Million |
0.327x | +132.43% |
| 2008-12-31 | CN¥1.14 Billion ≈ $167.42 Million |
CN¥161.18 Million ≈ $23.59 Million |
0.141x | -47.30% |
| 2007-12-31 | CN¥669.71 Million ≈ $98.00 Million |
CN¥179.02 Million ≈ $26.20 Million |
0.267x | +19.65% |
| 2006-12-31 | CN¥588.30 Million ≈ $86.09 Million |
CN¥131.43 Million ≈ $19.23 Million |
0.223x | +25.25% |
| 2005-12-31 | CN¥550.80 Million ≈ $80.60 Million |
CN¥98.24 Million ≈ $14.38 Million |
0.178x | +315.59% |
| 2004-12-31 | CN¥500.48 Million ≈ $73.24 Million |
CN¥21.48 Million ≈ $3.14 Million |
0.043x | +66.40% |
| 2003-12-31 | CN¥129.74 Million ≈ $18.98 Million |
CN¥3.35 Million ≈ $489.64K |
0.026x | -- |
About Hualan Biological EngineeringInc
Hualan Biological Engineering Inc. researches, develops, produces, and commercializes blood products, vaccines, and genetic engineering products in China and internationally. The company offers human serum albumin to treat blood loss trauma, shock caused by burns, intracranial pressure and persistent, liver cirrhosis, and kidney disease; edema for hypoproteinemia, neonatal hyperbilirubinemia, car… Read more